文献速递消化系统肿瘤

MUC16突变与胃癌肿瘤突变负荷及预后的关联

Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer.
PubMed 文献 · JAMA Oncol · 2018-01-01

该研究基于TCGA队列437例和亚洲队列256例胃癌样本,分析MUC16突变与肿瘤突变负荷(TML)及总生存的关系。发现MUC16突变在TCGA队列占38.4%、亚洲队列占22.3%,突变者TML显著更高且预后更好,该关联独立于POLE/BRCA1/2突变和突变特征。

要点

  • MUC16突变在胃癌中常见,TCGA队列38.4%、亚洲队列22.3%。
  • MUC16突变者TML显著更高,且与更好总生存独立相关。
  • MUC16突变样本中免疫应答和细胞周期通路显著改变。

核心结论

  • MUC16突变可能与胃癌更高TML、更好生存结局及免疫应答和细胞周期通路相关。

研究设计与样本

  • 对TCGA队列437例和亚洲队列256例胃癌样本的基因组数据进行统计分析,TCGA为发现集、亚洲队列为验证集。

主要发现

  • TCGA队列MUC16突变率38.4%(168/437),亚洲队列22.3%(57/256)。
  • MUC16突变者TML中位突变数更高:TCGA队列264 vs 115,亚洲队列134 vs 74,Wilcoxon秩和检验均P < .001。
  • MUC16突变与更好预后相关:TCGA队列中位总生存46.9个月 vs 26.7个月,log-rank P = .007;亚洲队列MUC16突变组中位总生存不可计算 vs 36.8个月,P = .04。
  • 控制年龄、性别、TNM分期、POLE和BRCA1/2突变及突变特征后,MUC16突变与总生存的关联仍有统计学意义(HR 0.61,95% CI 0.42-0.89;log-rank P = .01)。
  • MUC16突变样本中免疫应答和细胞周期调控通路为显著改变的通路(标准化富集分数1.70 [95% CI 1.57-1.79]和2.04 [95% CI 1.90-2.18];校正P < .001)。

关键数值与推荐

  • MUC16突变与更高TML的关联独立于POLE和BRCA1/2突变及突变特征:TCGA队列OR 1.87(95% CI 1.49-2.36),P < .001;亚洲队列OR 1.69(95% CI 1.25-2.29),P < .001。

临床怎么用

  • MUC16突变状态可能用于指导胃癌患者的免疫治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: MUC16, which encodes cancer antigen 125 (CA-125), is frequently mutated in gastric cancer (GC); however, its association with tumor mutation load (TML) and outcome in patients with GC has not been established, to date. OBJECTIVE: To investigate whether MUC16 mutations are associated with TML and prognosis in patients with GC. DESIGN, SETTING, AND PARTICIPANTS: Statistical analysis of genomic data from 437 GC samples obtained from The Cancer Genome Atlas (TCGA) and 256 samples from an Asian cohort. Both cohorts contained data of patients with GC involved in previous genomic studies. Data were obtained from TCGA on September 3, 2017, and from the Asian cohort on March 5, 2013, and analyzed from September 3 to December 1, 2017. The TCGA cohort was used as a discovery set and the Asian cohort as a validation set. Kaplan-Meier survival analysis and multivariate Cox and logistic regression models were applied. Regression models addressed confounding factors; Bayesian variant nonnegative matrix factorization was used to extract mutational signatures. The MutSigCV algorithm was used to identify significantly mutated genes. MAIN OUTCOMES AND MEASURES: Primary outcomes were mutation frequency, overall survival, and TML, calculated using Kaplan-Meier survival analysis, odds ratios (ORs), and significance of signaling pathways. RESULTS: MUC16 was mutated in 168 of 437 (38.4%) of the GC samples from the TCGA cohort and in 57 of 256 (22.3%) from the Asian cohort. In both cohorts, GC samples with MUC16 mutations exhibited significantly greater TML than those without MUC16 mutations (median mutation counts: TCGA cohort, 264 with MUC16 mutation vs 115 without; Asian cohort, 134 with MUC16 mutation vs 74 without; Wilcoxon rank sum test, both P < .001). This association was independent of mutations in POLE and BRCA1/2 and mutational signatures in the TCGA cohort (OR, 1.87; 95% CI, 1.49-2.36; P < .001) and the Asian cohort (OR, 1.69; 95% CI, 1.25-2.29; P < .001). MUC16 mutations were significantly associated with better prognosis in both cohorts (median overall survival, 46.9 [95% CI, 26.4-NA (not available)] vs 26.7 [95% CI, 20.2-43.1] months; log-rank test, P = .007 [TCGA cohort] and not calculable [the median overall survival of patients with GC and MUC16 mutations could not be calculated because more than half the patients in the group were alive] vs 36.8 months; P = .04 [Asian cohort]). The association remained statistically significant after controlling for age, sex, TNM stage, mutations in POLE and BRCA1/2, and mutational signatures (hazard ratio, 0.61 [95% CI, 0.42-0.89]; log rank test, P = .01). Immune response and cell cycle regulation circuits were among the top altered signaling pathways in samples with MUC16 mutations (normalized enrichment score, 1.70 [95% CI, 1.57-1.79] and 2.04 [95% CI, 1.90-2.18]; adjusted P < .001). The prognostic significance of MUC16 mutation identified in the TCGA cohort was validated in the Asian cohort. CONCLUSIONS AND RELEVANCE: These findings indicate that MUC16 mutations may be associated with higher TML, better survival outcomes, and immune response and cell cycle pathways. These findings may be immediately applicable for guiding immunotherapy treatment for patients with GC.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Li X, Pasche B, Zhang W, et al. Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer. JAMA Oncol. 2018. PMID: 30098163. doi:10.1001/jamaoncol.2018.2805

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。